A Double-blind, Placebo- and Active-controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Pediatric Patients 7-17 Years With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Levomilnacipran (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Allergan
- 10 Dec 2018 Planned End Date changed from 23 Nov 2021 to 21 Oct 2021.
- 10 Dec 2018 Planned primary completion date changed from 22 Sep 2021 to 21 Oct 2021.
- 12 Jul 2018 Status changed from not yet recruiting to recruiting.